ReviewJournal of the American Society of Nephrology : JASN2019
Iron Chelation as a Potential Therapeutic Strategy for AKI Prevention.
Review in Journal of the American Society of Nephrology : JASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04633889 (Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Intravenous amino acids to prevent acute kidney injury in cardiac surgery with cardiopulmonary bypass: a meta-analysis of randomized controlled trials.International journal of cardiology. Heart & vasculature · 2026Article
- Protective Effects of Selective β-Adrenoceptor Blockade on Renal Pathophysiology in a Catecholamine Storm of Rat.International journal of molecular sciences · 2026Article
- Dynamic Regulation of Ferroptosis in a Neonatal Rat Model of Postnatal Hypoxia-Induced Acute Kidney Injury.Antioxidants (Basel, Switzerland) · 2026Article
- Formononetin alleviated cisplatin-induced acute kidney injury by orchestrating renal tubular cell ferroptosis via PI3K/AKT/NRF2 pathway.Frontiers in pharmacology · 2026Article
- Impact of transfusion-associated iron overload on hepatic and renal function in patients with aplastic anemia: a retrospective cohort study of 145 cases.American journal of translational research · 2026Article
- Article
- Targeting macro- and micro-nutrient regulation of HNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Exploring the potential of repurposed deferoxamine: bridging challenges and novel formulation opportunities.Nanomedicine (London, England) · 2025Review
- Iron and ferroptosis in kidney disease: molecular and metabolic mechanisms.Frontiers in immunology · 2025Review
- Effect of verbascoside against acute kidney injury induced by rhabdomyolysis in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Iron as an emerging therapeutic target in critically ill patients.Critical care (London, England) · 2023Review
- Drugs in treating paediatric acute kidney injury.Pediatric nephrology (Berlin, Germany) · 2023Review
- Inhibition of retinoic acid signaling in proximal tubular epithelial cells protects against acute kidney injury.JCI insight · 2023Article
- Diagnosis, pathophysiology and preventive strategies for cardiac surgery-associated acute kidney injury: a narrative review.European journal of medical research · 2023Review
- Microvascular dysfunction following cardiopulmonary bypass plays a central role in postoperative organ dysfunction.Frontiers in medicine · 2023Review
- Targeting ferroptosis in ischemia/reperfusion renal injury.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Modulation of gentamicin-induced acute kidney injury by myo-inositol oxygenase via the ROS/ALOX-12/12-HETE/GPR31 signaling pathway.JCI insight · 2022Article
- NGAL/hepcidin-25 ratio and AKI subtypes in patients following cardiac surgery: a prospective observational study.Journal of nephrology · 2022Observational
- The Role of Ferroptosis in Acute Kidney Injury.Frontiers in molecular biosciences · 2022Review
- Ferroptosis and musculoskeletal diseases: "Iron Maiden" cell death may be a promising therapeutic target.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
AKI remains a major public health concern. Despite years of investigation, no intervention has been demonstrated to reliably prevent AKI in humans. Thus, development of novel therapeutic targets is urgently needed. An important role of iron in the pathophysiology of AKI has been recognized for over three decades. When present in excess and in nonphysiologic labile forms, iron is toxic to the kidneys and multiple other organs, whereas iron chelation is protective across a broad spectrum of insults. In humans, small studies have investigated iron chelation as a novel therapeutic strategy for prevention of AKI and extrarenal acute organ injury, and have demonstrated encouraging initial results. In this review, we examine the existing data on iron chelation for AKI prevention in both animal models and human studies. We discuss practical considerations for future clinical trials of AKI prevention using iron chelators, including selection of the ideal clinical setting, patient population, iron chelating agent, and dosing regimen. Finally, we compare the key differences among the currently available iron chelators, including pharmacokinetics, routes of administration, and adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.